- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 01.04. | SAB Biotherapeutics stock holds $6 target with Buy rating | 2 | Investing.com | ||
| 31.03. | SAB Biotherapeutics reports FY results | 3 | Seeking Alpha | ||
| 31.03. | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results | 233 | GlobeNewswire (Europe) | MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 05.02. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.01. | Why Is SAB BIO Stock Trading Lower On Tuesday? | 6 | Benzinga.com | ||
| 28.01. | Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings | 655 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59.
Planet... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 | 383 | GlobeNewswire (Europe) | SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy | 4 | GlobeNewswire (USA) | ||
| 06.01. | Here's Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10 | 1 | Insider Monkey | ||
| 07.11.24 | SAB Biotherapeutics GAAP EPS of -$1.12 | 1 | Seeking Alpha | ||
| 06.11.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update | 172 | GlobeNewswire (Europe) | Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov.... ► Artikel lesen | |
| 06.11.24 | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | 232 | GlobeNewswire (Europe) | FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)... ► Artikel lesen | |
| 05.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes | 543 | GlobeNewswire (Europe) | MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing... ► Artikel lesen | |
| 31.07.24 | SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer | 168 | GlobeNewswire (Europe) | MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is... ► Artikel lesen | |
| 20.06.24 | SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO | 205 | GlobeNewswire (Europe) | New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.05.24 | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer | 260 | GlobeNewswire (Europe) | MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human... ► Artikel lesen | |
| 21.05.24 | SAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | 294 | GlobeNewswire (Europe) | MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 102,10 | -0,10 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| CUREVAC | 2,882 | +0,77 % | CureVac-Aktie: Das wird zum Kracher! | News von Trading-Treff.de Eine erneut vernichtende Entwicklung nimmt nun die Aktie von CureVac. Das Papier hat am Donnerstag einen Abschlag in Höhe von -1,6% hinnehmen müssen. Damit ist die Aktie aktuell... ► Artikel lesen | |
| AMGEN | 246,90 | +0,47 % | Amgen im Stresstest - fällt die Biotech-Aktie zurück in die alte Seitwärtsrange? | Anzeige / WerbungDie Aktie von Amgen (ISIN: US0311621009) hatte sich zu Jahresbeginn beeindruckend aus dem Konsolidierungsmuster gelöst. Doch die jüngste Korrektur hat Spuren hinterlassen - und stellt... ► Artikel lesen | |
| NOVAVAX | 6,185 | -0,19 % | Novavax Aktie: Optimistische Umsatzprognosen! | Die Novavax-Aktie gewinnt über 20% nach positiven Signalen der FDA zur COVID-19-Impfstoffzulassung. Weitere Studien sind jedoch erforderlich. Die Novavax-Aktie zeigt heute eine beeindruckende Rallye... ► Artikel lesen | |
| BIOGEN | 104,70 | -0,24 % | Biogen's Skyclarys granted MHRA approval for rare movement disorder Friedreich's ataxia | ||
| MAINZ BIOMED | 2,775 | -100,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| VIKING THERAPEUTICS | 21,890 | -2,91 % | Viking Therapeutics Aktie: Wichtige Trends beobachtet | Biotech-Aktie mit starkem Jahresminus, doch Experten sehen hohes Potenzial. Entscheidende Quartalszahlen stehen bevor. Die Viking Therapeutics-Aktie zeigt sich zum Wochenstart mit leichten Gewinnen:... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,064 | -1,64 % | Intellia Therapeutics shares up after Wolfe upgrade | ||
| BIOCRYST PHARMACEUTICALS | 7,084 | -1,83 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2025 Financial Results on May 5 | ||
| CARDIOL THERAPEUTICS | 0,949 | +0,96 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 23.04.2025 / 15:24 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,984 | -1,31 % | PacBio, Davos Alzheimers Collaborative Join For North African Dementia Registry Project | WASHINGTON (dpa-AFX) - The Davos Alzheimers Collaborative, a global initiative to prevent Alzheimers disease and improve brain health, announced that PacBio (PACB) will be a technology partner... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 54,00 | -0,48 % | Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost | ||
| EXELIXIS | 32,420 | -0,80 % | Expert Outlook: Exelixis Through The Eyes Of 19 Analysts | ||
| VAXART | 0,350 | +10,97 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
| TEMPUS AI | 53,26 | -0,45 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen |
SAB BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.
